Evidence map›Paper›PMID 39361124›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2024

A pilot cross-sectional investigation of symptom clusters and associations with patient-reported outcomes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post COVID-19 Condition.

Breanna Weigel, Natalie Eaton-Fitch, Kiran Thapaliya, Sonya Marshall-Gradisnik

Abstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Breanna WeigelNational Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport Gold Coast, Brisbane, QLD, 4222, Australia. ncned@griffith.edu.au.ORCID http://orcid.org/0000-0001-8452-6656
Natalie Eaton-FitchNational Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport Gold Coast, Brisbane, QLD, 4222, Australia.ORCID http://orcid.org/0000-0002-0815-3162
Kiran ThapaliyaNational Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport Gold Coast, Brisbane, QLD, 4222, Australia.ORCID http://orcid.org/0000-0002-7667-770X
Sonya Marshall-GradisnikNational Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport Gold Coast, Brisbane, QLD, 4222, Australia.ORCID http://orcid.org/0000-0001-9270-2437

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is associated with long-term disability and poor quality of life (QoL). Cardinal ME/CFS symptoms (including post-exertional malaise, cognitive dysfunction and sleep disturbances) have been observed in Post COVID-19 Condition (PCC). To gain further insight into the potential role of ME/CFS as a post-COVID-19 sequela, this study investigates associations between symptoms and patient-reported outcomes, as well as symptom clusters.

methodsParticipants included Australian residents aged between 18 and 65 years formally diagnosed with ME/CFS fulfilling the Canadian or International Consensus Criteria or PCC meeting the World Health Organization case definition. Validated, self-administered questionnaires collected participants' sociodemographic and illness characteristics, symptoms, QoL and functional capacity. Associations between symptoms and patient-reported outcomes were investigated with multivariate linear regression models. Hierarchical cluster analysis was performed to identify symptom clusters.

resultsMost people with ME/CFS (pwME/CFS) and people with PCC (pwPCC) were female (n = 48/60, 80.0% and n = 19/30, 63.3%, respectively; p = 0.12). PwME/CFS were significantly younger (x̄=41.75, s = 12.91 years) than pwPCC (x̄=48.13, s =10.05 years; p =0.017). Autonomic symptoms (notably dyspnoea) were associated with poorer scores in most patient-reported outcome domains for both cohorts. None of the four symptom clusters identified were unique to ME/CFS or PCC. Clusters were largely delineated by the presence of gastrointestinal and neurosensory symptoms, illness duration, ME/CFS criteria met and total symptoms.

conclusionsIllness duration may explain differences in symptom burden between pwME/CFS and pwPCC. PCC diagnostic criteria must be refined to distinguish pwPCC at risk of long-term ME/CFS-like illness and subsequently deliver necessary care and support.

Indexed as

COVID-19Fatigue Syndrome, ChronicPatient Reported Outcome MeasuresQuality of LifeAdolescentAdultAgedAustraliaCluster AnalysisCross-Sectional StudiesFemaleHumansMaleMiddle AgedPilot ProjectsPost-Acute COVID-19 SyndromeLong COVIDMyalgic Encephalomyelitis/Chronic Fatigue SyndromePost-Acute Sequelae of COVID-19Post COVID-19 ConditionQuality of life

Identifiers

PMID39361124
PMCPMC11599292

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.